Antibody therapeutics in cancer - PubMed (original) (raw)

Review

. 2013 Sep 13;341(6151):1192-8.

doi: 10.1126/science.1241145.

Affiliations

• PMID: 24031011
• DOI: 10.1126/science.1241145

Review

Antibody therapeutics in cancer

Mark X Sliwkowski et al. Science. 2013.

Abstract

In a relatively short period of time, monoclonal antibodies have entered the mainstream of cancer therapy. Their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as long-sought vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. With ever more promising results from the clinic, the future will likely see continued growth in the discovery and development of therapeutic antibodies and their derivatives.

PubMed Disclaimer

Similar articles

• Therapeutic Antibodies in Cancer Therapy.
  Gasser M, Waaga-Gasser AM. Gasser M, et al. Adv Exp Med Biol. 2016;917:95-120. doi: 10.1007/978-3-319-32805-8_6. Adv Exp Med Biol. 2016. PMID: 27236554 Review.
• Herceptin.
  Shepard HM, Jin P, Slamon DJ, Pirot Z, Maneval DC. Shepard HM, et al. Handb Exp Pharmacol. 2008;(181):183-219. doi: 10.1007/978-3-540-73259-4_9. Handb Exp Pharmacol. 2008. PMID: 18071947 Review.
• ErbB receptors and signaling pathways in cancer.
  Hynes NE, MacDonald G. Hynes NE, et al. Curr Opin Cell Biol. 2009 Apr;21(2):177-84. doi: 10.1016/j.ceb.2008.12.010. Epub 2009 Feb 7. Curr Opin Cell Biol. 2009. PMID: 19208461 Review.
• [Development of monoclonal antibody therapy for brain tumors].
  Mishima K. Mishima K. Nihon Rinsho. 2005 Sep;63 Suppl 9:569-77. Nihon Rinsho. 2005. PMID: 16201583 Review. Japanese. No abstract available.
• The EGF receptor family as targets for cancer therapy.
  Mendelsohn J, Baselga J. Mendelsohn J, et al. Oncogene. 2000 Dec 27;19(56):6550-65. doi: 10.1038/sj.onc.1204082. Oncogene. 2000. PMID: 11426640 Review.

Cited by

• Utilization of Microfluidic Droplet-Based Methods in Diagnosis and Treatment Methods of Hepatocellular Carcinoma: A Review.
  Zajanckauskaite A, Lingelbach M, Juozapaitė D, Utkus A, Rukšnaitytė G, Jonuškienė G, Gulla A. Zajanckauskaite A, et al. Genes (Basel). 2024 Sep 25;15(10):1242. doi: 10.3390/genes15101242. Genes (Basel). 2024. PMID: 39457366 Free PMC article. Review.
• Monoclonal antibodies: From magic bullet to precision weapon.
  Aboul-Ella H, Gohar A, Ali AA, Ismail LM, Mahmoud AEE, Elkhatib WF, Aboul-Ella H. Aboul-Ella H, et al. Mol Biomed. 2024 Oct 11;5(1):47. doi: 10.1186/s43556-024-00210-1. Mol Biomed. 2024. PMID: 39390211 Free PMC article. Review.
• Internal Fragments Enhance Middle-Down Mass Spectrometry Structural Characterization of Monoclonal Antibodies and Antibody-Drug Conjugates.
  Wei B, Lantz C, Ogorzalek Loo RR, Campuzano IDG, Loo JA. Wei B, et al. Anal Chem. 2024 Feb 13;96(6):2491-2499. doi: 10.1021/acs.analchem.3c04526. Epub 2024 Jan 31. Anal Chem. 2024. PMID: 38294207
• Rapid isolation of anti-idiotype aptamers for quantification of human monoclonal antibodies against SARS-CoV-2 spike protein.
  Wen K, Dai W, Meng X, Lin Q, Wei J, Tong L, Taylor SK, Rudchenko SA, Stojanovic MN, Kalantarov G, Trakht I. Wen K, et al. Biosens Bioelectron. 2024 Feb 15;246:115842. doi: 10.1016/j.bios.2023.115842. Epub 2023 Nov 20. Biosens Bioelectron. 2024. PMID: 38042051
• Understanding the promising role of antibody drug conjugates in breast and ovarian cancer.
  Babbar R, Vanya, Bassi A, Arora R, Aggarwal A, Wal P, Dwivedi SK, Alolayan S, Gulati M, Vargas-De-La-Cruz C, Behl T, Ojha S. Babbar R, et al. Heliyon. 2023 Oct 30;9(11):e21425. doi: 10.1016/j.heliyon.2023.e21425. eCollection 2023 Nov. Heliyon. 2023. PMID: 38027672 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal